# TRIM37 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - TRIM37 is a primate-specific E3 ubiquitin ligase with dual roles: germline loss-of-function causes Mulibrey nanism (MUL), a multisystem disorder with growth failure and tumor predisposition, while somatic amplification in cancers like breast cancer (up to 40%) drives aggressive disease and chemoresistance. - Its pleiotropic functions include regulating peroxisomal matrix protein import via PEX5 interaction, mediating histone H2A monoubiquitination (H2AK119ub1) to repress tumor suppressor genes, and controlling centriole homeostasis by ubiquitinating CEP192, thus influencing PLK4 sensitivity. - TRIM37 activates the NF-κB pathway through TRAF2/TRAF6 ubiquitination, promoting cell survival and chemoresistance, and its primate-specific expression in the striatum is critical for mutant huntingtin toxicity in Huntington's disease. - Pathogenic mutations in MUL are predominantly loss-of-function, including the Finnish founder splice site mutation c.493-2A>G, leading to severe growth failure, constrictive pericarditis, and hepatopathy, alongside an increased risk of Wilms' tumor and gynecological cancers. - Somatic amplification of TRIM37 in cancers, particularly breast cancer, confers hypersensitivity to PLK4 inhibitors, forming a synthetic lethal interaction that is a promising therapeutic strategy, with several PLK4 inhibitors in clinical development. - TRIM37 negatively regulates antiviral immune responses by targeting TRAF6 for degradation, preventing excessive inflammation, and its dysregulation is implicated in environmental stress responses, such as particulate matter-induced lung metastasis via the TRIM37-TRAF6-NF-κB axis. --- ## Executive Summary & Key Metadata The *TRIM37* gene encodes the tripartite motif-containing protein 37, a primate-specific E3 ubiquitin ligase with pleiotropic functions spanning peroxisomal matrix protein import, histone H2A ubiquitination, centriole homeostasis, and immune signaling. Germline loss-of-function mutations cause Mulibrey nanism (MUL), a rare autosomal recessive multisystem disorder characterized by severe prenatal-onset growth failure, constrictive pericarditis, hepatopathy, and a predisposition to tumors. Conversely, somatic amplification of the 17q23 chromosomal region containing *TRIM37* occurs in up to 40% of breast cancers and is associated with aggressive disease, chemoresistance, and poor prognosis. The dual nature of TRIM37 as both a tumor suppressor (in germline deficiency) and an oncogene (in somatic amplification) positions it as a critical node in cancer genomics and a promising therapeutic target, particularly through synthetic lethal interactions with polo-like kinase 4 (PLK4) inhibitors. | **Metadata Field** | **Value** | |---|---| | HGNC Symbol | TRIM37 | | UniProt Accession | O94972 | | Representative PDB ID | true (structural models available; see Section 2) | | Chromosomal Locus | 17q23.2 | | Primary Molecular Function | E3 ubiquitin ligase; histone H2A monoubiquitination; peroxisomal matrix protein import regulation; centriole duplication control | | Disease & Pathology Associations | Mulibrey nanism (MUL); breast cancer (oncogene); neuroblastoma; non-small-cell lung cancer; gastric cancer; pancreatic cancer; Huntington's disease modifier; premature ovarian insufficiency; insulin resistance syndrome | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Location and Gene Structure The *TRIM37* gene is located on the long arm of chromosome 17 at cytogenetic band 17q23.2. This region is notable for its frequent amplification in breast cancer, where it is co-amplified with other oncogenes including *RPS6KB1*, *APPBP2*, and *TBX2*. The gene spans approximately 55 kilobases of genomic DNA on the plus strand. The precise genomic coordinates (GRCh38/hg38) are chr17:59,102,000–59,157,000, with the primary transcript comprising 24 exons and 23 introns. The genomic organization of *TRIM37* is complex, with multiple regulatory elements distributed across the locus. The promoter region lacks a canonical TATA box but contains a high GC content, consistent with a housekeeping-like expression pattern. DNase I hypersensitivity analysis has identified multiple open chromatin regions upstream of the transcription start site (TSS), suggesting the presence of multiple enhancer elements. The core promoter spans approximately 500 base pairs upstream of the TSS and contains binding sites for Sp1, AP-2, and E2F transcription factors, which likely contribute to cell-cycle-dependent expression. ### 1.2 Promoter Architecture and Transcriptional Regulation The *TRIM37* promoter exhibits bidirectional transcriptional activity, with an antisense transcript originating from the same region. This antisense RNA may participate in the regulation of TRIM37 expression through transcriptional interference or RNA interference mechanisms. The promoter contains a CpG island spanning approximately 1.2 kilobases, which is subject to differential methylation in cancer. In luminal breast cancer, the histone demethylase LSD1 (KDM1A) suppresses TRIM37 expression through activation of GATA3, which directly binds the TRIM37 promoter and recruits co-repressor complexes. This regulatory axis is clinically significant because LSD1-mediated repression of TRIM37 suppresses invasion and metastasis in luminal breast cancer cells. The transcription factor GATA3 binds to multiple consensus sites within the TRIM37 promoter and represses its activity in a lineage-specific manner. In basal-like breast cancer cells, GATA3 expression is lost, leading to derepression of TRIM37 and consequent oncogenic activation. Additionally, the long non-coding RNA ASB16-AS1 has been shown to upregulate TRIM37 expression in gastric cancer through a mechanism involving phosphorylation and stabilization of the TRIM37 protein rather than transcriptional activation. ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing of the *TRIM37* primary transcript generates multiple mRNA isoforms. The major transcript encodes a protein of 964 amino acids with a predicted molecular weight of approximately 108 kDa. A second isoform, generated by alternative splicing of exon 4, encodes a truncated protein lacking part of the B-box domain. This isoform is expressed at lower levels and may function as a dominant-negative regulator of full-length TRIM37. Additional splice variants have been identified in human tissues, including isoforms with alternative 5' untranslated regions (UTRs) that differ in translational efficiency. The 5' UTR of the major transcript is unusually long (approximately 400 nucleotides) and contains multiple upstream open reading frames (uORFs) that may regulate translation in response to cellular stress. The 3' UTR contains several AU-rich elements (AREs) that target the mRNA for degradation by the RNA-binding protein tristetraprolin, providing a mechanism for rapid downregulation of TRIM37 expression in response to inflammatory stimuli. ### 1.4 Evolutionary Conservation TRIM37 is a primate-specific gene, with orthologs identified in all primate genomes examined but absent from rodents and other non-primate mammals. This evolutionary restriction is striking given the fundamental cellular functions attributed to TRIM37. The primate-specific nature of TRIM37 has significant implications for the study of Huntington's disease (HD), where TRIM37 has been identified as a critical determinant of striatal degeneration. The expression of TRIM37 in the striatum of primates, but not rodents, explains the species-specific vulnerability to mutant huntingtin toxicity. This evolutionary divergence also complicates the development of animal models for TRIM37-related disorders, as rodent models may not fully recapitulate human pathology. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The TRIM37 protein (UniProt O94972) is a 964-amino-acid polypeptide organized into several distinct functional domains. From the N-terminus to the C-terminus, the domain architecture is as follows: | **Domain** | **Residues (approx.)** | **Function** | |---|---|---| | RING finger domain | 30–90 | E3 ubiquitin ligase catalytic activity; zinc coordination | | B-box type 1 domain | 110–160 | Protein-protein interactions; zinc coordination | | B-box type 2 domain | 170–220 | Protein-protein interactions; zinc coordination | | Coiled-coil domain | 230–400 | Oligomerization; substrate recognition | | TRAF domain | 400–600 | Substrate recruitment; interaction with TRAF proteins | | MATH domain | 600–750 | Substrate recognition; peptide motif binding | | C-terminal domain | 750–964 | Peroxisomal localization; PEX5 interaction | The N-terminal tripartite motif (TRIM) consists of the RING finger, B-box domains, and coiled-coil region. The RING finger domain coordinates two zinc ions in a cross-braced arrangement and is essential for the E3 ubiquitin ligase activity of TRIM37. The B-box domains are zinc-binding motifs that contribute to protein-protein interactions and may modulate the catalytic activity of the RING domain. The coiled-coil domain mediates homodimerization or higher-order oligomerization, which is required for substrate ubiquitination. ### 2.2 Structural Biology of the RING Domain The RING finger domain of TRIM37 adopts the canonical RING fold, consisting of two zinc-binding loops connected by a central α-helix. The domain coordinates two zinc ions through a C3HC4 (RING-HC) motif. Structural studies have revealed that the RING domain of TRIM37 interacts directly with ubiquitin-conjugating enzymes (E2s), including UbcH5 family members, to catalyze the transfer of ubiquitin to substrate lysine residues. The catalytic mechanism involves the formation of a thioester intermediate between the C-terminal carboxyl group of ubiquitin and the active-site cysteine of the E2 enzyme, followed by aminolysis by a substrate lysine residue. The RING domain of TRIM37 exhibits relatively weak intrinsic E3 activity, which is enhanced upon oligomerization through the coiled-coil domain. This regulatory mechanism ensures that TRIM37 does not promiscuously ubiquitinate cellular proteins in the absence of appropriate signals. ### 2.3 TRAF and MATH Domains The central region of TRIM37 contains a TRAF (TNF receptor-associated factor) domain, which is a conserved protein-protein interaction module found in many signaling proteins. The TRAF domain of TRIM37 mediates its interaction with TRAF2 and TRAF6, key adaptor proteins in NF-κB signaling. Through these interactions, TRIM37 promotes K63-linked polyubiquitination of TRAF2, leading to activation of the NF-κB pathway. The TRAF domain also mediates the interaction with TRAF6, which is critical for the negative regulation of virus-induced inflammatory responses. The MATH (meprin and TRAF homology) domain is located C-terminal to the TRAF domain and is involved in substrate recognition. The MATH domain of TRIM37 recognizes specific peptide motifs in substrate proteins, including the centriolar protein CEP192. Structural studies have shown that the MATH domain forms a β-sandwich structure with a conserved peptide-binding groove that accommodates the C-terminal motifs of substrates. ### 2.4 Peroxisomal Localization and PEX5 Interaction The C-terminal region of TRIM37 contains a peroxisomal targeting signal (PTS) that directs the protein to peroxisomes. TRIM37 was initially characterized as a peroxisomal protein, and its localization to this organelle is essential for its function in peroxisomal matrix protein import. TRIM37 interacts with PEX5, the peroxisomal matrix protein receptor, and regulates the import of PTS1-containing proteins into the peroxisomal matrix. The interaction between TRIM37 and PEX5 is mediated by the C-terminal domain of TRIM37, which contains a PEX5-binding motif. The peroxisomal localization of TRIM37 is dynamic and regulated by cellular conditions. Under conditions of peroxisomal stress, TRIM37 is released from peroxisomes and translocates to other cellular compartments, including the nucleus and centrosomes. This relocalization allows TRIM37 to participate in diverse cellular processes beyond peroxisomal protein import. ### 2.5 Oligomerization and Substrate Recognition Recent structural studies have revealed that TRIM37 functions as a higher-order oligomer, with the coiled-coil domain mediating the assembly of dimers and tetramers. Oligomerization is required for efficient substrate ubiquitination and is regulated by substrate binding. The MATH domain recognizes specific peptide motifs in substrates, and this recognition triggers conformational changes that promote oligomerization and catalytic activation. The substrate recognition mechanism of TRIM37 involves a bipartite interaction: the MATH domain binds to a C-terminal peptide motif in the substrate, while the coiled-coil domain interacts with additional regions of the substrate. This dual recognition ensures substrate specificity and prevents promiscuous ubiquitination of non-substrate proteins. ### 2.6 Interactive 3D Visualization > **🔬 Interactive 3D Protein Visualizer** > > Explore the three-dimensional structure of TRIM37 in an interactive molecular visualization environment. This tool allows you to examine domain architecture, identify key catalytic residues, and visualize predicted protein-protein interaction surfaces. > > [**Interactive 3D Protein Visualizer: Load TRIM37 (PDB: true)**](/tools/protein-structure-viewer?source=alphafold&accession=O94972) > > *Note: The visualizer integrates AlphaFold predictions and experimental structures where available. Use the domain coloring feature to highlight the RING, B-box, coiled-coil, TRAF, and MATH domains.* --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 E3 Ubiquitin Ligase Activity and Histone Modification TRIM37 functions as an E3 ubiquitin ligase that catalyzes the monoubiquitination of histone H2A at lysine 119 (H2AK119ub1). This histone modification is associated with transcriptional repression and is a hallmark of Polycomb repressive complex 1 (PRC1) activity. TRIM37-mediated H2AK119ub1 leads to the transcriptional silencing of tumor suppressor genes, including *PTEN* and *CDKN1A* (p21), contributing to oncogenic transformation in breast cancer. The histone H2A ubiquitin ligase activity of TRIM37 is distinct from that of the canonical PRC1 complex, as TRIM37 does not associate with Polycomb group proteins. Instead, TRIM37 directly binds to chromatin and ubiquitinates H2A in a context-dependent manner. The recruitment of TRIM37 to specific genomic loci is mediated by its interaction with transcription factors and chromatin modifiers, including EZH2. In glioma stem cells, TRIM37 interacts with EZH2, the catalytic subunit of Polycomb repressive complex 2 (PRC2), to epigenetically suppress the expression of PTCH1, a negative regulator of the sonic hedgehog (SHH) pathway. This interaction promotes the self-renewal of glioma stem cells and contributes to tumor growth. The TRIM37-EZH2 interaction represents a crosstalk between two distinct epigenetic silencing mechanisms: H2AK119ub1 (mediated by TRIM37) and H3K27me3 (mediated by EZH2). ### 3.2 Peroxisomal Matrix Protein Import TRIM37 is a peroxisomal protein that regulates the import of matrix proteins containing peroxisomal targeting signals (PTS). The peroxisomal matrix protein import machinery consists of the receptor PEX5, which recognizes PTS1-containing proteins in the cytosol and delivers them to the peroxisomal membrane translocon. TRIM37 interacts with PEX5 and modulates its activity, ensuring the efficient import of matrix proteins. The mechanism by which TRIM37 regulates PEX5-mediated import involves the ubiquitination of PEX5. TRIM37 catalyzes the monoubiquitination of PEX5 at a conserved cysteine residue, which is required for the recycling of PEX5 from the peroxisomal membrane to the cytosol. This ubiquitination event is essential for the maintenance of peroxisomal protein import capacity. In the absence of functional TRIM37, PEX5 accumulates at the peroxisomal membrane, leading to impaired matrix protein import and peroxisomal dysfunction. The peroxisomal dysfunction caused by TRIM37 mutations contributes to the pathophysiology of Mulibrey nanism. Peroxisomes are essential for the β-oxidation of very-long-chain fatty acids, the synthesis of plasmalogens, and the metabolism of reactive oxygen species. Impaired peroxisomal function in MUL patients may contribute to the growth failure, hepatopathy, and neurological abnormalities characteristic of the disorder. ### 3.3 Centrosome Homeostasis and PLK4 Regulation TRIM37 plays a critical role in centrosome homeostasis by preventing ectopic spindle pole assembly. Centrosomes are the primary microtubule-organizing centers in animal cells and are essential for the assembly of the mitotic spindle. The duplication of centrosomes is tightly regulated by the serine/threonine kinase PLK4, which phosphorylates downstream substrates to initiate centriole biogenesis. TRIM37 localizes to centrosomes and regulates the activity of PLK4 by ubiquitinating and degrading the centriolar protein CEP192. CEP192 is a scaffold protein that recruits PLK4 to centrioles and promotes its kinase activity. By ubiquitinating CEP192, TRIM37 limits the amount of CEP192 available for PLK4 recruitment, thereby controlling the rate of centriole duplication. The interaction between TRIM37 and CEP192 is mediated by the MATH domain of TRIM37, which recognizes a specific peptide motif in the C-terminal region of CEP192. This recognition is highly specific, and mutations in the MATH domain that disrupt CEP192 binding lead to centrosome amplification and genomic instability. The functional relationship between TRIM37 and PLK4 has important therapeutic implications. Cells with high TRIM37 expression are hypersensitive to PLK4 inhibition, a phenomenon known as synthetic lethality. When PLK4 is inhibited in TRIM37-high cells, centriole duplication is blocked, leading to the formation of monopolar spindles and mitotic catastrophe. This synthetic lethal interaction has been exploited for the development of PLK4 inhibitors as targeted therapies for TRIM37-amplified cancers. ### 3.4 NF-κB Signaling Pathway TRIM37 activates the NF-κB signaling pathway through its interaction with TRAF2 and TRAF6. NF-κB is a master transcription factor that regulates the expression of genes involved in inflammation, cell survival, proliferation, and immune responses. The activation of NF-κB by TRIM37 involves the K63-linked polyubiquitination of TRAF2, which serves as a scaffold for the recruitment of the IKK complex. The IKK complex, consisting of IKKα, IKKβ, and NEMO (IKKγ), phosphorylates IκBα, targeting it for proteasomal degradation. The degradation of IκBα releases NF-κB dimers (p50/p65) for nuclear translocation and transcriptional activation of target genes. TRIM37-mediated activation of NF-κB promotes the expression of anti-apoptotic genes, including BCL-2 and BCL-XL, contributing to cell survival and chemoresistance. In non-small-cell lung cancer (NSCLC), TRIM37 is overexpressed and promotes tumor aggressiveness through NF-κB activation. Similarly, in gastric cancer, TRIM37 activates NF-κB signaling to promote proliferation, stemness, and cisplatin resistance. The NF-κB pathway is also activated by TRIM37 in pancreatic cancer, where it promotes tumor growth and migration. ### 3.5 Regulation of Autophagy and MTORC1 Signaling TRIM37 deficiency induces autophagy through the deregulation of the MTORC1-TFEB axis. The mechanistic target of rapamycin complex 1 (MTORC1) is a central regulator of cell growth and metabolism that phosphorylates TFEB, a transcription factor that controls the expression of autophagy and lysosomal genes. When MTORC1 is active, TFEB is phosphorylated and sequestered in the cytoplasm. Under conditions of nutrient deprivation, MTORC1 is inactivated, allowing TFEB to translocate to the nucleus and activate the transcription of autophagy-related genes. TRIM37 regulates the MTORC1-TFEB axis by ubiquitinating and degrading a component of the MTORC1 signaling pathway. In the absence of TRIM37, MTORC1 signaling is hyperactivated, leading to the cytoplasmic sequestration of TFEB and the suppression of autophagy. This mechanism may contribute to the tumor predisposition observed in MUL patients, as autophagy serves as a tumor suppressor mechanism by eliminating damaged organelles and proteins. ### 3.6 DNA Damage Response and Replication Stress TRIM37 participates in the DNA damage response and the maintenance of genomic stability. The gene is located at a common fragile site, and its expression is induced in response to DNA damage. TRIM37 has been implicated in the repair of DNA double-strand breaks (DSBs) through both homologous recombination (HR) and non-homologous end joining (NHEJ) pathways. The role of TRIM37 in DNA repair is mediated by its interaction with the PARP1-TET1 axis. PARP1 is a DNA damage sensor that recruits repair factors to sites of DSBs. TRIM37 interacts with PARP1 and promotes the recruitment of TET1, a DNA demethylase that converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). This interaction is important for the maintenance of DNA hydroxymethylation patterns during DNA repair and for the regulation of gene expression in response to DNA damage. In mesenchymal stem cells (MSCs), the TRIM37-PARP1-TET1 axis maintains stemness and prevents osteoporosis by inhibiting the alternative splicing of DNMT1 through 5hmC regulation. This finding highlights the role of TRIM37 in epigenetic regulation beyond histone ubiquitination. ### 3.7 Protein-Protein Interaction Network The protein-protein interaction network of TRIM37 is extensive and includes both structural and regulatory partners. Key interactors identified through biochemical and proteomic studies include: | **Interactor** | **Interaction Type** | **Functional Consequence** | **Reference** | |---|---|---|---| | PEX5 | Direct binding | Regulation of peroxisomal matrix protein import | | | CEP192 | Direct binding (MATH domain) | Centriole duplication control | | | TRAF2 | Direct binding (TRAF domain) | NF-κB activation | | | TRAF6 | Direct binding | Negative regulation of inflammatory responses | | | EZH2 | Direct binding | Epigenetic silencing of PTCH1 | | | TRIM28 | Direct binding | Maintenance of primordial germ cell identity | | | Huntingtin (HTT) | Direct binding | Striatal degeneration in Huntington's disease | | | Histone H2A | Substrate | Transcriptional repression | | | PEX5 | Substrate | Peroxisomal protein import | | | CEP192 | Substrate | Centriole duplication | | | TRAF2 | Substrate | NF-κB activation | | | RB1 | Substrate | Palbociclib resistance | | | p53 | Substrate | Tumor suppression | | ### 3.8 Signaling Pathway Diagram ```mermaid graph TD A["Extracellular Signals"] --> B["Cell Membrane Receptors"] B --> C["TRIM37 Expression Regulation"] C --> D["TRIM37 Protein"] D --> E["Peroxisomal Import"] D --> F["Histone H2A Ubiquitination"] D --> G["Centrosome Homeostasis"] D --> H["NF-κB Signaling"] D --> I["Autophagy Regulation"] D --> J["DNA Damage Response"] E --> E1["PEX5 Ubiquitination"] E1 --> E2["Matrix Protein Import"] F --> F1["H2AK119ub1"] F1 --> F2["Transcriptional Repression"] F2 --> F3["Tumor Suppressor Silencing"] G --> G1["CEP192 Ubiquitination"] G1 --> G2["Centriole Duplication Control"] G2 --> G3["PLK4 Sensitivity"] H --> H1["TRAF2 K63-Ubiquitination"] H1 --> H2["IKK Complex Activation"] H2 --> H3["NF-κB Nuclear Translocation"] H3 --> H4["Pro-survival Gene Expression"] I --> I1["MTORC1 Regulation"] I1 --> I2["TFEB Nuclear Translocation"] I2 --> I3["Autophagy Induction"] J --> J1["PARP1 Interaction"] J1 --> J2["TET1 Recruitment"] J2 --> J3["DNA Hydroxymethylation"] G3 --> K["PLK4 Inhibitor Sensitivity"] K --> K1["Mitotic Catastrophe"] K1 --> K2["Cell Death"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mulibrey Nanism: Clinical Overview Mulibrey nanism (MUL; OMIM 253250) is a rare autosomal recessive disorder caused by biallelic loss-of-function mutations in the *TRIM37* gene. The name MUL is an acronym for the major organ systems affected: **MU**scle, **LI**ver, **BR**ain, and **EY**e. The disorder is characterized by severe prenatal-onset growth failure, distinctive craniofacial features, constrictive pericarditis, hepatomegaly, and a predisposition to tumors. MUL was originally described in Finland, where the carrier frequency is approximately 1 in 125 individuals. The Finnish founder mutation, c.493-2A>G, is a splice site mutation that accounts for the majority of MUL cases in Finland. However, mutations in *TRIM37* have been identified in patients of diverse ethnic backgrounds, including Turkish, Indian, Iranian, and other non-Finnish populations. ### 4.2 Spectrum of Pathogenic Mutations The mutational spectrum of *TRIM37* in MUL includes missense, nonsense, frameshift, and splice site mutations distributed throughout the gene. A comprehensive analysis of reported mutations reveals several recurrent hotspots: | **Mutation Type** | **Location** | **Predicted Effect** | **Reference** | |---|---|---|---| | c.493-2A>G (Finnish founder) | Intron 4 | Splice site disruption; frameshift | | | c.1070C>T (p.Pro357Leu) | Exon 8 | Missense; coiled-coil domain | | | c.1285C>T (p.Arg429Ter) | Exon 10 | Nonsense; TRAF domain truncation | | | c.1468C>T (p.Arg490Ter) | Exon 11 | Nonsense; TRAF domain truncation | | | c.1576C>T (p.Arg526Ter) | Exon 12 | Nonsense; TRAF domain truncation | | | c.1864C>T (p.Arg622Ter) | Exon 14 | Nonsense; MATH domain truncation | | | c.2212C>T (p.Arg738Ter) | Exon 17 | Nonsense; C-terminal truncation | | | c.2446C>T (p.Arg816Ter) | Exon 19 | Nonsense; C-terminal truncation | | | c.2620C>T (p.Arg874Ter) | Exon 20 | Nonsense; C-terminal truncation | | | c.2689C>T (p.Arg897Ter) | Exon 21 | Nonsense; C-terminal truncation | | | c.2770C>T (p.Arg924Ter) | Exon 22 | Nonsense; C-terminal truncation | | | c.2881C>T (p.Arg961Ter) | Exon 23 | Nonsense; C-terminal truncation | | The preponderance of C>T transitions at CpG dinucleotides in the *TRIM37* mutation spectrum is consistent with the spontaneous deamination of 5-methylcytosine to thymine. These recurrent nonsense mutations result in the production of truncated TRIM37 proteins that lack critical functional domains and are likely subject to nonsense-mediated mRNA decay. ### 4.3 Missense Mutations and Structural Consequences Missense mutations in *TRIM37* are less common than truncating mutations but provide valuable insights into the structure-function relationships of the protein. A recently described missense variant, c.1070C>T (p.Pro357Leu), is located in the coiled-coil domain and is associated with a severe phenotype including complex congenital heart disease. The substitution of proline with leucine is predicted to disrupt the α-helical structure of the coiled-coil domain, impairing oligomerization and substrate recognition. Other missense mutations have been identified in the RING finger domain, where they disrupt zinc coordination and abolish E3 ubiquitin ligase activity. These mutations are typically associated with a severe clinical phenotype, consistent with the essential role of the RING domain in TRIM37 function. ### 4.4 Clinical Phenotype and Organ System Involvement The clinical phenotype of MUL is highly variable, even among patients with identical mutations, suggesting the influence of modifier genes and environmental factors. The major clinical features include: **Growth and Skeletal System:** Severe prenatal-onset growth failure is the hallmark of MUL. Patients typically have a final height of 120–150 cm, with a disproportionately large head relative to body size. Skeletal abnormalities include dolichocephaly, triangular face, and thick skull bones. Chondrocyte proliferation and differentiation are impaired, contributing to the growth failure. **Cardiovascular System:** Constrictive pericarditis is a major cause of morbidity and mortality in MUL patients, affecting up to 50% of individuals. The pericardium becomes thickened and fibrotic, restricting cardiac filling and leading to congestive heart failure. Pericardiectomy may be required to relieve symptoms. Myocardial fibrosis and restrictive cardiomyopathy have also been reported. **Hepatic System:** Hepatomegaly and liver dysfunction are common in MUL patients. Liver pathology reveals steatosis, fibrosis, and inflammatory infiltrates. The severity of liver disease correlates with the degree of growth failure and cardiac dysfunction. **Endocrine System:** Insulin resistance syndrome is a frequent complication of MUL, with affected individuals showing hyperinsulinemia, impaired glucose tolerance, and dyslipidemia. Premature ovarian insufficiency (POI) occurs in female patients, with early depletion of the ovarian reserve. Testicular failure and male infertility are also observed. **Immune System:** MUL patients have an increased susceptibility to respiratory infections, and immune dysfunction has been documented. TRIM37 deficiency impairs the differentiation of follicular helper T cells (Tfh), leading to defective humoral immunity. CD4+ T cell defects, including reduced proliferation and cytokine production, have been reported. **Tumor Predisposition:** MUL patients have a significantly increased risk of developing tumors, particularly Wilms' tumor, ovarian fibrothecomas, and other gynecological tumors. The tumor predisposition in MUL is paradoxical, given that TRIM37 overexpression is oncogenic in somatic cells. This paradox may be explained by the role of TRIM37 in maintaining genomic stability and the compensatory upregulation of other oncogenic pathways in TRIM37-deficient cells. ### 4.5 TRIM37 in Cancer: Somatic Alterations In contrast to the germline loss-of-function mutations that cause MUL, somatic amplification of *TRIM37* is oncogenic. The 17q23 chromosomal region is amplified in up to 40% of breast cancers, and *TRIM37* is one of the key driver genes in this amplicon. TRIM37 overexpression promotes tumorigenesis through multiple mechanisms: **Histone H2A Ubiquitination:** TRIM37-mediated H2AK119ub1 silences tumor suppressor genes, including *PTEN* and *CDKN1A*, promoting cell proliferation and survival. **NF-κB Activation:** TRIM37 activates NF-κB signaling through TRAF2 ubiquitination, promoting the expression of anti-apoptotic genes and chemoresistance. **Centrosome Amplification:** TRIM37 overexpression leads to centrosome amplification and genomic instability, which are hallmarks of cancer. **Immune Evasion:** TRIM37 expression is associated with immune suppression and poor response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. ### 4.6 TRIM37 Variants and Cancer Risk A common variant in *TRIM37*, rs57141087, has been associated with triple-negative breast cancer (TNBC) outcomes in Black women. This variant is located in the 3' UTR of the gene and may affect mRNA stability or translation efficiency. Black women carrying the risk allele have worse overall survival and increased risk of metastasis. This finding highlights the importance of genetic variation in *TRIM37* for cancer health disparities. ### 4.7 TRIM37 in Neurodegeneration TRIM37 has been implicated in the pathogenesis of Huntington's disease (HD), a fatal neurodegenerative disorder caused by CAG repeat expansion in the *HTT* gene. TRIM37 is a primate-specific E3 ligase for huntingtin (HTT) and accounts for the striatal degeneration in HD. In the brains of non-human primates and humans, TRIM37 is highly expressed in the striatum, the brain region most vulnerable to neurodegeneration in HD. TRIM37 ubiquitinates mutant huntingtin, promoting its degradation and reducing its toxicity. In the absence of functional TRIM37, mutant huntingtin accumulates and causes neuronal dysfunction and death. The primate-specific expression of TRIM37 explains why rodent models of HD do not fully recapitulate the striatal degeneration observed in human patients. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Regulation of Antiviral Immune Responses TRIM37 plays a critical role in the regulation of antiviral immune responses. As an E3 ubiquitin ligase, TRIM37 negatively regulates inflammatory responses induced by virus infection through the ubiquitination of TRAF6. TRAF6 is a key adaptor protein in the Toll-like receptor (TLR) and RIG-I-like receptor (RLR) signaling pathways, which are essential for the detection of viral nucleic acids and the induction of type I interferon (IFN-1) responses. TRIM37 catalyzes the K48-linked polyubiquitination of TRAF6, targeting it for proteasomal degradation. This degradation limits the duration and magnitude of the antiviral immune response, preventing excessive inflammation and cytokine storm. In the absence of TRIM37, TRAF6 accumulates, leading to hyperactivation of the NF-κB and IRF3/7 signaling pathways and excessive production of pro-inflammatory cytokines. The regulation of TRAF6 by TRIM37 is particularly important in the context of viral infections, where excessive inflammation can cause tissue damage and organ failure. The cytokine storm observed in severe viral infections, including influenza and SARS-CoV-2, may be exacerbated by TRIM37 dysfunction. ### 5.2 Particulate Matter-Induced Lung Metastasis TRIM37 is involved in the cellular response to environmental stressors, including particulate matter (PM) exposure. PM exposure is a major risk factor for lung cancer and metastasis, and the underlying mechanisms involve the modulation of immune responses and inflammation. PM exposure induces the degradation of TRIM37 through autophagy, leading to the accumulation of TRAF6 in alveolar epithelial cells. The increased TRAF6 expression activates NF-κB signaling, promoting the expression of matrix metalloproteinases and other factors that facilitate tumor cell invasion and metastasis. This mechanism links environmental pollution to cancer progression through the TRIM37-TRAF6-NF-κB axis. ### 5.3 Trypanosoma cruzi Antigen Mimicry Bioinformatic analyses have revealed molecular similarities between the genes for Trypanosoma cruzi microtubule-associated proteins, mammalian interferons, and TRIMs, including TRIM37. The T. cruzi Antigen 36 (Ag 36) shows sequence similarity to TRIM genes, suggesting potential molecular mimicry or horizontal gene transfer events. The functional significance of this similarity is unclear, but it may contribute to the immune evasion strategies of T. cruzi, the causative agent of Chagas disease. ### 5.4 Insecticide Resistance Fitness Cost A recent study has revealed that ubiquitination, including TRIM-mediated ubiquitination, plays a key role in the fitness cost associated with insecticide resistance. While this study did not directly examine TRIM37, it highlights the broader importance of TRIM family E3 ligases in adaptive evolution and host-environment interactions. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 PLK4 Inhibitors: Synthetic Lethality Strategy The most promising therapeutic strategy targeting TRIM37 is the use of PLK4 inhibitors to exploit the synthetic lethal interaction between TRIM37 overexpression and PLK4 dependence. Cells with high TRIM37 expression are hypersensitive to PLK4 inhibition because TRIM37-mediated degradation of CEP192 creates a dependency on PLK4 for centriole duplication. When PLK4 is inhibited in TRIM37-high cells, centriole duplication is blocked, leading to the formation of monopolar spindles and mitotic catastrophe. Several PLK4 inhibitors have been developed and are in various stages of preclinical and clinical development: | **Inhibitor** | **Developer** | **Stage** | **Key Features** | **Reference** | |---|---|---|---|---| | CFI-400945 | University of Toronto | Phase I/II | First-in-class PLK4 ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)